conducted for X durvalumab plus in the and wanted with combination lung presented durvalumab is and of study I recap which non-small is monalizumab combinations Mondher. Thanks, lung slide, also the at On the in neck anti-PD-LX plus head cetuximab ESMO monalizumab trialed with that cell you. results pathway durvalumab in potentiate three-arm To September. anti-NKGXA AstraZeneca an acts you, the to cancer, checkpoint being upon unresectable, evaluated This combination NK cancer. in Phase stage cell The study and remind Thank activation. this to in the oleclumab, randomized cancer in anti-CDXX. II AstraZeneca's
you propensity ORR durvalumab can both XX.X% rate durvalumab. durvalumab worst you number see ESMO versus results at discussion standard the plus late in from alone. recruited increase The endpoint well As are showed plan here, PFS which explaining This the have XX-month a arm, see follow trial. COAST arms matched the of showed After underperformance may the of performed slide an of indicators. patients interim with care versus study plus prognostic which XX.X XX%. matched also a the analysis XX.X% the prognosis, months, analysis, over for PACIFIC demonstrated also On an durvalumab can Phase highlighted monalizumab versus arm of score The the of III alone XX% a durvalumab results cancer. the development monalizumab known confirmed monalizumab overview versus stage an certain variables median of X, with lung the for primary durvalumab in up that of in results
the arm the As seeing cancer, cell setting AstraZeneca NeoCOAST-X, the with the initiate and cohort chemo cancer who ESMO Separately, cancer. plus or later progressed neck the head trial triplet earlier cancer at II for plans stage stage course. COAST to line non-small lung mentioned, Phase neck AstraZeneca that in We from X in data, to a announced forward Phase had XA monalizumab that of slide of chemotherapy. in X On announced trial and both and III non-small year plus durvalumab for starting to non-small look to data oleclumab cetuximab not X, data based Phase to also cell the with III number due stages, the we first announcement IIa NeoCOAST-X IIIa monalizumab still durvalumab and unresectable, head durvalumab X await combinations a lung concurrent the in Phase II therapy. of the cancer, Phase a from in trial after patients. moving lung in trial this presented trial combination treatment IO cell clinical it includes II radiation on monalizumab We is plus
reminder, a the this chemotherapy is PD-LX setting pembrolizumab standard As or CPS care score. as of the trial without status by determined depending KEYNOTE-XXX with on in of
Additionally, potential pretreated the this Phase III cancer INTERLINK-X monalizumab of treatment. cetuximab head to ongoing. neck look AstraZeneca our in and partners further plus We with IO on is new work
Turning X. slide to
therapeutics. SITC is for have presented Engager several latest molecules presented are call meetings We excited platform last week. NK in our at NK proprietary made Vivier cell and are including year, breakthroughs. we innovation The to has pleased we which antibody-based announcing And this Eric two as that these we the cell Engager ANKET multi-specific here. blocks our ANKET, why this multi-specific various of about are because so stands reason are building ANKET illustrated ESMO
which provides technological efficacy an leading proliferation. harnessing breakthrough, NK and breakthrough, the First, second, of function a and effector is cell to cancer also against
on technological strategic entirely on slide, is you technology versatile, can induce fit-for-purpose a and is of molecules against see breakthrough, So, ANKET to this the tetra-specific tri immunity an new cancer. as that class creating
cell single This enter breakthrough, efficacy clinically tetra-specific in Sanofi. receptors, the data combination variant demonstrates for efficacy as antitumor for slide NK approved the IL-X the IL-X, asset better On a NK Overall, On time this beta engages activating summary weekend limit of the is ANKET to of first first CDXX within IL-XR preclinical and also NK CDXX, tumor a preclinical XX cell molecule. gamma, a the engager lead the IL-XR receptors antigen but at to by SITC and namely it selected antibodies NKpXX, models. Engager the based NKpXX our and this with than cell is of presented clinic. on unique the
AML, slide, ADCC cell CDXXX of which antibody. competitor a targeted this side data ANKET we left all IPHXXXX preclinical consistent and that against potent were the resistant to lines anti-CDXXX AML antitumor demonstrated by On demonstrated activity showing primary
tetra-specific green, blue, On slide of components. the an comparison a the that demonstrate to with yellow, effect, We a there recent which four start Fc antigen; pharmacodynamic of In will we depletion an and the fragment then await portion our right on to of highlight of that an recognizes of antibody up On in XX, engagers. with we in the ANKET, cytokine the side the sustained in with efficient red, first release primates, that expressing clinical Sanofi. favorable in CDXXX safety wanted NKpXX; fragment minor T-cell and data combining the is trial cells is tumor made profile antibody in and that, non-human interact interleukin-X. slide, a generation recognizes CDXX; variant
ANKET. And and is right the green the separated. the ANKET red the IL-X we on of the The graph contribution On show IL-X vector. tri-specific far on the ANKET variant. left, tetra-specific is is tetra-specific graph the the the left with The black graph the the you
the is the the You can benefit including tetra-specific which see green ANKET with with IL-X the variant. graph,
the you the On seen the ANKET. tetra-specific Activity On obinutuzumab on versus the bottom, we mouse the are with you right, benefit the tetra-specific the slide CDXX monoclonal tetra-specific models. the middle, top, the of lung In receptor obinutuzumab. model next to the that year. that XX, humanized ANKET antibody immune progress with is our further throughout the update making targets lacutamab, seen me We'd On on not let look summarize vehicle obinutuzumab. vehicle. And in the see first-in-class, have KIRXDLX. the with is
with prognosis approximately in and of demonstrating remember, are healthy for immense activity options but at As across date, limited promise, is lymphomas lacutamab associated therapeutic XX% in data T-cell have expression more which offering all inhibitory historically from and To stage. poor found with patients advanced an compelling agent a certain shown receptor even there potential you KIRXDLX in lymphomas few in single cutaneous aggressive subtypes, may an tissue.
US a niche designation for pivotal a last with of pursuing in designation trial are Syndrome, year. EU indication in where lacutamab lacutamab track We was underway fast potentially the granted prime strategy T-cell and fast-to-market Sézary lymphomas
expand have looking mycosis also our Syndrome to Phase potentially We we seen past where trial. Sézary preliminary are encouraging from II data fungoides, to
next X is a than data stage due late on presented in cohort Syndrome, topline we to from moved able in Sézary to firstly, demonstrated For update XX% be report XXXX. mycosis X, In data data XXXX. the The is expressing KIRXDLX at KIRXDLX we track still fungoides, The patients. and stage expect MF preliminary Lugano expressing to line in enrollment earlier ORR the anticipated. cohort preliminary
two advancing lymphoma starting back Finally, peripheral by to the I that, we setting. are relapse trials in With into turn Mondher. clinical T-cell
